All In Biotech

Drug Trial Radar · NCT07562152

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 570 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

570

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Jun 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Immuneering CorporationIndustry
Sponsor type
Industry
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Conditions

  • Pancreatic Cancer
  • Pancreatic Cancer Metastatic
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Adenocarcinoma

Interventions

  • AtebimetinibDrug

    Once daily oral tablets

  • GnPDrug

    Standard of care regimen for intravenous infusions of gemcitabine and nab-paclitaxel weekly for three weeks followed by one week without an infusion

  • mGnPDrug

    Biweekly intravenous infusions of chemotherapy (gemcitabine and nab-paclitaxel)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Up to approximately 2 years

Locations

76 sites in 9 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • City of Hope

    Phoenix, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California San Diego

    San Diego, California · Recruiting

  • Poudre Valley Health Care, Inc

    Fort Collins, Colorado · Recruiting

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado · Recruiting

  • Medical Oncology Hematology Consultants

    Newark, Delaware · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida · Recruiting

  • Florida Cancer Specialists - South

    Sarasota, Florida · Recruiting

  • Florida Cancer Specialists - North

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists - East

    West Palm Beach, Florida · Recruiting

  • Piedmont Cancer Institute

    Atlanta, Georgia · Recruiting

  • Piedmont Healthcare

    Atlanta, Georgia · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • City of Hope

    Chicago, Illinois · Recruiting

  • OSF Medical Center

    Peoria, Illinois · Recruiting

  • University of Kansas Cancer Center

    Fairway, Kansas · Recruiting

  • Maryland Oncology

    Columbia, Maryland · Recruiting

  • Missouri Cancer Associates

    Columbia, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers

    Las Vegas, Nevada · Recruiting

  • Regional Cancer Care

    Belleville, New Jersey · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • FirstHealth of the Carolinas

    Pinehurst, North Carolina · Recruiting

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Willamette Valley Cancer Institute

    Eugene, Oregon · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Prisma Health

    Greenville, South Carolina · Recruiting

  • Avera Cancer Institute Research

    Sioux Falls, South Dakota · Recruiting

  • West Cancer Center

    Germantown, Tennessee · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Texas Oncology - West Texas

    Abilene, Texas · Recruiting

  • Texas Oncology - Austin

    Austin, Texas · Recruiting

  • Texas Oncology - San Antonio

    San Antonio, Texas · Recruiting

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.